1,3-Diaza-Spiro-Octane Derivatives NOP Receptor Selectivity
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current analgesics for pain management, particularly for chronic and neuropathic pain, have limited therapeutic windows due to severe side effects and reduced effectiveness, and there is a need for compounds that selectively target the NOP receptor system with minimal impact on the MOP receptor system to distinguish between central and peripheral nervous activity.
Innovation Solution
Development of 1,3-diaza-spiro-[3.4]-octane derivatives that act as pharmacologically active compounds, specifically designed to target the NOP receptor system with reduced activity on the MOP receptor system, thereby minimizing central nervous system-mediated adverse effects and optimizing pain relief with reduced side effects.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If strong opioids acting at the MOP receptor site are used to treat pain, then effective analgesia is achieved, but severe side effects such as nausea, vomiting, constipation, dizziness, somnolence, respiratory depression, physical dependence and abuse occur
Solution Approach 1:
The patent extracts and isolates the analgesic effect from the harmful side effects by developing compounds that selectively target the NOP receptor system while minimizing interaction with the MOP receptor system. This separation allows the beneficial pain-relieving properties to be maintained while removing the adverse effects associated with traditional opioid therapy.
Solution Approach 2:
The invention applies local quality by creating compounds with selective receptor affinity - the molecules are designed to interact preferentially with NOP receptors in specific neural pathways while avoiding MOP receptors. This selective binding pattern creates different functional outcomes in different receptor locations, achieving analgesia without the broad-spectrum side effects of non-selective opioids.
2Reliability
If MOP receptor agonists are used for chronic and neuropathic pain, then pain relief is provided, but effectiveness is reduced and tolerance develops
Solution Approach 1:
The patent employs parameter changes by modifying the molecular structure and pharmacological parameters of opioid compounds to shift their receptor selectivity profile. The compounds are designed with specific structural features that alter their binding affinity ratios between NOP and MOP receptors, thereby changing the therapeutic parameters to achieve sustained effectiveness without tolerance development.
3Object-generated harmful factors
If peripherally restricted opioid receptor ligands are provided to avoid CNS-mediated adverse effects, then side effects are reduced, but central nervous system analgesia is limited
Solution Approach 1:
The patent uses the NOP receptor system as an intermediary mechanism to achieve central analgesic effects without direct CNS penetration. The compounds act peripherally on NOP receptors to modulate pain signaling, and this peripheral activation of the NOP system indirectly produces central analgesia through endogenous mechanisms, bypassing the need for direct CNS exposure.
Data Source
AI summary
The invention relates to 1,3-diaza-spiro-[3.4]-octane derivatives, their preparation and use in medicine, particularly in various neurological disorders, including but not limited to pain, neurodegenerative disorders, neuroinflammatory disorders, neuropsychiatric disorders, substance abuse/dependence.